What Spyre Therapeutics does

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel half-life extended monoclonal antibodies for inflammatory bowel disease (IBD) and rheumatic diseases. The company was rebranded in late 2023 from Aeglea BioTherapeutics and is publicly traded on NASDAQ under the ticker SYRE, headquartered in Waltham, Massachusetts, with 101–250 employees. Its core scientific platform applies the YTE modification to FcRn-binding regions of antibodies, producing a greater than 3x half-life extension that enables quarterly or twice-annual subcutaneous dosing compared with bi-weekly dosing for approved standards of care such as Takeda's Entyvio.

The pipeline comprises three monotherapy candidates (SPY001 targeting α4β7, SPY002 targeting TL1A, and SPY003 targeting IL-23) plus three fixed-dose combination products (SPY120, SPY130, SPY230) coformulated in single injectors, and a distinct anti-TL1A antibody (SPY072) for rheumatic indications. All candidates are investigational and being evaluated in Phase 2 studies including the SKYLINE-UC and SKYWAY-RD trials. Phase 2 data for SPY001 showed 40% clinical remission at Week 12 versus 27% for Entyvio, with 51% endoscopic improvement versus 41%, while SPY003 demonstrated approximately an 85-day confirmed half-life in interim Phase 1 results.

The business model is pre-revenue biopharmaceutical product sales contingent on regulatory approval; no products are approved or commercialized, and there are no published prices. The company has no commercial distribution infrastructure, but has appointed a Chief Commercial Officer (Kate Tansey Chevlen) in January 2026 to prepare for potential commercialization. As of year-end 2025, Spyre held approximately $757 million in cash, cash equivalents, and marketable securities, expected to fund operations into the second half of 2028, supported by capital raises totaling approximately $866.5 million across April 2026 offerings, $316.2 million in October 2025, and a $180 million private placement in March 2024.

Name

Spyre Therapeutics

Legal name

Spyre Therapeutics, Inc.

Website

https://spyre.com

Company type

Public

Founded year

2023

Operating status

Operating

Headcount range

101–250 employees

Short description

Spyre Therapeutics is a clinical-stage biotechnology company developing YTE-modified monoclonal antibodies (SPY001, SPY002, SPY003, SPY072) and fixed-dose combinations for inflammatory bowel disease and rheumatic diseases, targeting quarterly or twice-annual dosing versus bi-weekly standards of care.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals (Immunology / IBD / Rheumatic Disease)

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Gastroenterology Specialty Pharmaceuticals (HLAIACAE)

akta.pro secondary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Inflammatory bowel disease therapeutics
• Monoclonal antibody development
• Clinical-stage biotechnology
• Immunology pipeline drugs
• Rheumatic disease biologics

Headquarters

HQ city

Sunrise

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Biopharmaceutical Product Sales: Pre-revenue clinical-stage biotechnology company. The company is developing a pipeline of novel antibody therapeutics targeting inflammatory bowel disease and rheumatic diseases. Upon successful clinical development and regulatory approval, the company plans to commercialize its pipeline candidates. No products have been approved or commercialized yet.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel, half-life extended monoclonal antibodies targeting validated mechanisms (α4β7, TL1A, IL-23) for the treatment of inflammatory bowel disease (ulcerative colitis, Crohn's disease) and rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis). The pipeline includes monotherapy candidates (SPY001, SPY002, SPY003, SPY072) and fixed-dose combination products (SPY120, SPY130, SPY230), all incorporating the YTE modification technology for extended half-life enabling quarterly or twice annual subcutaneous dosing.

Product overview

Spyre Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel half-life extended monoclonal antibodies targeting validated mechanisms for gastrointestinal and rheumatic diseases. The company's portfolio includes monotherapy candidates (SPY001 targeting α4β7, SPY002 targeting TL1A, SPY003 targeting IL-23) and combination products (SPY120, SPY130, SPY230) that pair these antibodies for enhanced efficacy. All antibodies incorporate the YTE modification for extended half-life enabling quarterly or twice annual dosing. The company is also developing SPY072, a distinct anti-TL1A antibody for rheumatic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

• SPY001 Novel, half-life extended monoclonal antibody targeting α4β7 for the potential treatment of inflammatory bowel disease (IBD), with demonstrated similar potency and selectivity as vedolizumab in preclinical studies and a differentiated pharmacokinetic profile supporting quarterly or twice annual maintenance dosing. Currently in Phase 2 clinical development (SKYLINE-UC).
• SPY002 Novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of inflammatory bowel disease, exhibiting comparable or superior potency to first-generation anti-TL1As in head-to-head preclinical studies. Currently in Phase 2 clinical development (SKYLINE-UC trial; achieved 33% clinical remission and 42% endoscopic improvement at Week 12).
• SPY003 Novel, half-life extended monoclonal antibody targeting IL-23 for the potential treatment of inflammatory bowel disease, exhibiting comparable potency to risankizumab in head-to-head preclinical studies and an approximately 85-day confirmed half-life in interim Phase 1 results. Currently in Phase 2 clinical development.
• SPY120 High-concentration fixed-dose combination of SPY001 (anti-α4β7) and SPY002 (anti-TL1A) for the potential treatment of IBD, with superior efficacy compared to either monotherapy alone in preclinical colitis models, coformulated for delivery in a single injector on a quarterly or twice annual basis.
• SPY130 High-concentration fixed-dose combination of SPY001 (anti-α4β7) and SPY003 (anti-IL-23) for the potential treatment of IBD, demonstrating additive efficacy in preclinical colitis models, coformulated for single-injector delivery on a quarterly or twice annual basis.
• SPY230 High-concentration fixed-dose combination of SPY002 (anti-TL1A) and SPY003 (anti-IL-23) for the potential treatment of IBD, demonstrating additive efficacy in preclinical models, coformulated for single-injector delivery on a quarterly or twice annual basis.
• SPY072 Novel, half-life extended monoclonal antibody targeting TL1A for the potential treatment of rheumatic diseases including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). Distinct from SPY002 which is being studied in IBD. Currently in Phase 2 clinical development (SKYWAY-RD).

Quantifiable outcome

• SPY001 achieved 40% clinical remission rate at Week 12 vs 27% for Entyvio in ulcerative colitis
• +4 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• AbbVie: Markets Skyrizi (risankizumab, anti-IL-23) and Humira in IBD/rheumatic diseases. Directly competes with SPY003 in IL-23 mechanism and sets the efficacy bar Spyre's programs must clear.
• Johnson & Johnson: Markets Tremfya (anti-IL-23) and Stelara in IBD and rheumatic indications. Major incumbent across Spyre's two therapeutic areas with established commercial infrastructure.
• Eli Lilly: Markets mirikizumab (Omvoh) in ulcerative colitis and acquired Morphic for its integrin pipeline. Direct competitor in IBD and a likely strategic acquirer of immunology-focused biotechs.
• Takeda Pharmaceutical: Markets Entyvio (vedolizumab, anti-α4β7), the direct competitor to SPY001 in ulcerative colitis and Crohn's. Entyvio's commercial performance is the primary benchmark for Spyre's α4β7 program.
• Merck & Co. Acquired Prometheus Biosciences for $10.8B to access its TL1A program. Now competing with Spyre's SPY002/SPY072 in TL1A for IBD and rheumatic indications with substantially larger commercial resources.
• Roche: Develops immunology biologics including TL1A programs (acquired Telavant) and established IBD/rheumatic franchises. Competes with Spyre across multiple targeted mechanisms in overlapping indications.

Direct peers

• Apogee Therapeutics: Clinical-stage immunology biotech developing antibody therapies for inflammatory diseases, with overlapping TL1A and IL-23 programs in IBD. Board member Michael Henderson is CEO of Apogee, creating direct portfolio overlap with Spyre.
• Prometheus Biosciences: Was a clinical-stage IBD-focused biotech developing TL1A antibody therapy (PRA023) before being acquired by Merck for $10.8B. Directly comparable pipeline focus and the source of multiple Spyre team members.
• Morphic Holding: Clinical-stage biotech developing oral integrin therapies for IBD, acquired by Eli Lilly for ~$3.2B. Directly comparable as an IBD-focused immunology platform targeting validated mechanisms with differentiated delivery.

Emerging players

• Mirador Therapeutics: Recently formed immunology biotech led by Mark McKenna (Spyre board member). Pursues precision immunology approaches in inflammation and immunology with overlapping scientific leadership.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/spyretx
• LinkedInlinkedin.com/company/spyre-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds5 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spyre Therapeutics